$1.35 Billion is the total value of Rock Springs Capital Management LP's 137 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 21.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AET | Buy | AETNA INC NEW | $53,749,000 | +16.4% | 440,100 | +7.1% | 3.98% | +2.8% |
| ACHC | Buy | ACADIA HEALTHCARE COMPANY IN | $46,370,000 | +12.3% | 837,000 | +11.7% | 3.43% | -0.8% |
| AGN | Buy | ALLERGAN PLC | $41,850,000 | -8.7% | 181,100 | +5.9% | 3.10% | -19.3% |
| TSRO | Buy | TESARO INC | $40,344,000 | +141.5% | 480,000 | +26.5% | 2.99% | +113.4% |
| PFE | Buy | PFIZER INC | $37,175,000 | +20.8% | 1,055,800 | +1.7% | 2.75% | +6.7% |
| RDUS | Buy | RADIUS HEALTH INC | $31,881,000 | +25.4% | 867,500 | +7.3% | 2.36% | +10.8% |
| ONCE | Buy | SPARK THERAPEUTICS INC | $31,189,000 | +82.1% | 610,000 | +5.1% | 2.31% | +60.9% |
| ISRG | Buy | INTUITIVE SURGICAL INC | $29,102,000 | +15.3% | 44,000 | +4.8% | 2.15% | +1.8% |
| GILD | Buy | GILEAD SCIENCES INC | $28,671,000 | -5.5% | 343,700 | +4.1% | 2.12% | -16.5% |
| AAAP | Buy | ADVANCED ACCELERATOR APPLICsponsored ads | $27,846,000 | -4.5% | 921,000 | +10.6% | 2.06% | -15.7% |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $27,497,000 | -13.3% | 235,500 | +3.4% | 2.04% | -23.4% |
| CI | Buy | CIGNA CORPORATION | $26,468,000 | +58.1% | 206,800 | +69.5% | 1.96% | +39.6% |
| WCG | Buy | WELLCARE HEALTH PLANS INC | $25,157,000 | +17.9% | 234,500 | +2.0% | 1.86% | +4.2% |
| CELG | Buy | CELGENE CORP | $25,101,000 | +4.7% | 254,500 | +6.3% | 1.86% | -7.5% |
| GWPH | Buy | GW PHARMACEUTICALS PLCads | $24,724,000 | +133.1% | 270,000 | +83.7% | 1.83% | +105.8% |
| MDCO | Buy | MEDICINES CO | $22,885,000 | +14.0% | 680,500 | +7.7% | 1.69% | +0.7% |
| SHPG | New | SHIRE PLCsponsored adr | $22,097,000 | – | 120,042 | +100.0% | 1.64% | – |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $18,612,000 | +16.3% | 409,500 | +1.2% | 1.38% | +2.8% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $18,470,000 | +8.8% | 1,000,000 | +11.7% | 1.37% | -3.9% |
| HTWR | Buy | HEARTWARE INTL INC | $17,960,000 | +196.2% | 311,000 | +61.1% | 1.33% | +161.8% |
| PCRX | Buy | PACIRA PHARMACEUTICALS INC | $15,937,000 | -7.9% | 472,500 | +44.7% | 1.18% | -18.6% |
| TBPH | Buy | THERAVANCE BIOPHARMA INC | $15,883,000 | +29.9% | 700,000 | +7.6% | 1.18% | +14.7% |
| MCK | Buy | MCKESSON CORP | $14,540,000 | +19.3% | 77,900 | +0.5% | 1.08% | +5.4% |
| BMY | Buy | BRISTOL MYERS SQUIBB CO | $14,453,000 | +33.1% | 196,500 | +15.6% | 1.07% | +17.6% |
| PEN | Buy | PENUMBRA INC | $14,429,000 | +37.3% | 242,500 | +6.1% | 1.07% | +21.2% |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $14,414,000 | +29.1% | 102,000 | +19.3% | 1.07% | +14.1% |
| COLL | Buy | COLLEGIUM PHARMACEUTICAL INC | $14,398,000 | -30.7% | 1,215,000 | +6.1% | 1.07% | -38.8% |
| BIIB | Buy | BIOGEN INC | $13,941,000 | +0.8% | 57,650 | +8.5% | 1.03% | -11.0% |
| WBA | Buy | WALGREENS BOOTS ALLIANCE INC | $13,357,000 | +28.4% | 160,400 | +29.9% | 0.99% | +13.4% |
| INCY | Buy | INCYTE CORP | $12,397,000 | +31.1% | 155,000 | +18.8% | 0.92% | +15.9% |
| ARDX | Buy | ARDELYX INC | $11,131,000 | +35.1% | 1,275,000 | +20.2% | 0.82% | +19.4% |
| DERM | Buy | DERMIRA INC | $10,381,000 | +73.1% | 354,900 | +22.4% | 0.77% | +53.2% |
| HLS | Buy | HEALTHSOUTH CORP | $10,287,000 | +31.4% | 265,000 | +27.4% | 0.76% | +16.2% |
| ACHN | Buy | ACHILLION PHARMACEUTICALS IN | $10,238,000 | +8.7% | 1,312,500 | +7.6% | 0.76% | -3.9% |
| WMGI | Buy | WRIGHT MED GROUP N V | $9,517,000 | +17.0% | 547,900 | +11.8% | 0.70% | +3.4% |
| CLSD | New | CLEARSIDE BIOMEDICAL INC | $9,487,000 | – | 1,353,326 | +100.0% | 0.70% | – |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $8,791,000 | +3.2% | 113,000 | +9.4% | 0.65% | -8.8% |
| XNPT | Buy | XENOPORT INC | $8,413,000 | +69.6% | 1,195,000 | +8.6% | 0.62% | +49.8% |
| EW | Buy | EDWARDS LIFESCIENCES CORP | $8,327,000 | +24.2% | 83,500 | +9.9% | 0.62% | +9.6% |
| HOLX | New | HOLOGIC INC | $7,958,000 | – | 230,000 | +100.0% | 0.59% | – |
| EVHC | Buy | ENVISION HEALTHCARE HLDGS IN | $7,383,000 | +36.1% | 291,000 | +9.4% | 0.55% | +20.2% |
| ITCI | Buy | INTRA CELLULAR THERAPIES INC | $7,376,000 | +41.5% | 190,000 | +1.3% | 0.55% | +24.9% |
| VRTX | Buy | VERTEX PHARMACEUTICALS INC | $7,355,000 | +10.3% | 85,500 | +1.9% | 0.54% | -2.5% |
| OPHT | Buy | OPHTHOTECH CORP | $7,272,000 | +234.0% | 142,500 | +176.7% | 0.54% | +195.6% |
| ARA | New | AMERICAN RENAL ASSOCIATES HO | $7,243,000 | – | 250,000 | +100.0% | 0.54% | – |
| New | CORSICANTO LTDnote 3.500% 1/1 | $7,214,000 | – | 7,000,000 | +100.0% | 0.53% | – | |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL IN | $6,921,000 | -7.7% | 141,500 | +19.4% | 0.51% | -18.6% |
| CHRS | Buy | COHERUS BIOSCIENCES INC | $6,756,000 | +12.8% | 400,000 | +41.8% | 0.50% | -0.4% |
| NVTA | Buy | INVITAE CORP | $6,343,000 | -17.6% | 858,380 | +14.1% | 0.47% | -27.1% |
| FPRX | Buy | FIVE PRIME THERAPEUTICS INC | $6,327,000 | +7.8% | 153,000 | +5.9% | 0.47% | -4.9% |
| CRME | Buy | CARDIOME PHARMA CORP | $6,144,000 | +26.2% | 1,200,000 | +0.8% | 0.46% | +11.5% |
| EPZM | Buy | EPIZYME INC | $6,118,000 | -14.3% | 597,500 | +1.4% | 0.45% | -24.2% |
| HRC | New | HILL ROM HLDGS INC | $6,054,000 | – | 120,000 | +100.0% | 0.45% | – |
| REGN | Buy | REGENERON PHARMACEUTICALS | $5,937,000 | -0.2% | 17,000 | +3.0% | 0.44% | -11.6% |
| New | EGALET CORPnote 5.500% 4/0 | $5,923,000 | – | 7,800,000 | +100.0% | 0.44% | – | |
| PRTK | Buy | PARATEK PHARMACEUTICALS INC | $5,821,000 | +72.1% | 418,500 | +87.7% | 0.43% | +52.3% |
| INSM | Buy | INSMED INC | $4,905,000 | -14.0% | 497,500 | +10.6% | 0.36% | -24.1% |
| ALDR | Buy | ALDER BIOPHARMACEUTICALS INC | $4,507,000 | +88.7% | 180,500 | +85.1% | 0.33% | +67.0% |
| TNDM | Buy | TANDEM DIABETES CARE INC | $4,486,000 | -8.4% | 595,000 | +5.8% | 0.33% | -19.0% |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $3,981,000 | -20.5% | 300,000 | +11.1% | 0.30% | -29.8% |
| RIGL | Buy | RIGEL PHARMACEUTICALS INC | $3,903,000 | +28.2% | 1,750,000 | +19.5% | 0.29% | +13.3% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $3,713,000 | -28.4% | 680,000 | +10.8% | 0.28% | -36.6% |
| FGEN | Buy | FIBROGEN INC | $3,692,000 | -15.0% | 225,000 | +10.3% | 0.27% | -25.0% |
| EARS | Buy | AURIS MED HLDG AG | $3,562,000 | +24.2% | 850,000 | +7.9% | 0.26% | +10.0% |
| INVA | New | INNOVIVA INC | $3,548,000 | – | 336,900 | +100.0% | 0.26% | – |
| GI | Buy | ENDOCHOICE HLDGS INC | $3,479,000 | +13.2% | 710,000 | +20.3% | 0.26% | 0.0% |
| PRGO | Buy | PERRIGO CO PLC | $3,436,000 | -10.5% | 37,900 | +26.3% | 0.25% | -21.1% |
| TSRO | New | TESARO INCcall | $3,362,000 | – | 40,000 | +100.0% | 0.25% | – |
| NBRV | Buy | NABRIVA THERAPEUTICS AGsponsored adr | $3,195,000 | -6.2% | 426,000 | +12.1% | 0.24% | -16.8% |
| MRUS | New | MERUS N V | $2,883,000 | – | 360,811 | +100.0% | 0.21% | – |
| STE | New | STERIS PLC | $2,750,000 | – | 40,000 | +100.0% | 0.20% | – |
| AGLE | New | AEGLEA BIOTHERAPEUTICS INC | $2,547,000 | – | 524,089 | +100.0% | 0.19% | – |
| TTPH | Buy | TETRAPHASE PHARMACEUTICALS I | $1,828,000 | -1.3% | 425,000 | +6.2% | 0.14% | -12.9% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $1,626,000 | +31.4% | 98,000 | +25.6% | 0.12% | +15.4% |
| RLYP | New | RELYPSA INC | $1,388,000 | – | 75,000 | +100.0% | 0.10% | – |
| LIFE | Buy | ATYR PHARMA INC | $1,205,000 | -29.4% | 433,500 | +0.0% | 0.09% | -37.8% |
| CERN | New | CERNER CORP | $1,172,000 | – | 20,000 | +100.0% | 0.09% | – |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $983,000 | +6.3% | 33,000 | +4.8% | 0.07% | -6.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.